| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,736 | -15,240 |
| Depreciation | - | 104 |
| Stock-based compensation expense | 8,482 | 5,854 |
| Depreciation | 158 | 100 |
| Amortization of debt discount and issuance costs | 174 | 104 |
| Non-cash interest expense | 463 | 390 |
| Loss on debt extinguishment | -527 | -527 |
| Pik interest incurred but not paid on term loan | 0 | 0 |
| Amortization of right-of-use asset | 1,268 | 835 |
| Gain on short-term investments | 41 | -41 |
| Inventory write-downs | 140 | 93 |
| Loss on disposal of property and equipment | -2 | -2 |
| Accounts receivable | 2,087 | 704 |
| Inventory | 4,894 | 3,058 |
| Prepaid expenses and other assets | -134 | -671 |
| Accounts payable | 1,655 | 1,703 |
| Accrued liabilities | 2,530 | -120 |
| Deferred revenue | 93 | 141 |
| Operating lease liabilities | -1,380 | -911 |
| Net cash used in operating activities | -11,512 | -9,568 |
| Acquisition of property and equipment | 235 | 205 |
| Proceeds from sale of short-term investments | 0 | 0 |
| Net cash (used in) provided by investing activities | -235 | -205 |
| Proceeds from issuance of stock-Follow On Offering | 69,654 | 69,704 |
| Repurchase of common stock | 49,546 | 49,546 |
| Proceeds from issuance of common stock under employee plans | 1,152 | 1,151 |
| Taxes withheld and paid related to net share settlement of equity awards | 455 | 402 |
| Proceeds from issuance of stock-At The Market Equity Offering | 232 | 232 |
| Proceeds from debt, net of discounts and issuance costs-At The Market Equity Offering | 58,435 | 58,568 |
| Repayment of debt-At The Market Equity Offering | 60,507 | 60,507 |
| Net cash provided by financing activities | 18,965 | 19,200 |
| Net increase (decrease) in cash and cash equivalents | 7,218 | 9,427 |
| Cash and cash equivalents at beginning of period | 13,552 | - |
| Cash and cash equivalents at end of period | 20,770 | - |
NeuroPace Inc (NPCE)
NeuroPace Inc (NPCE)